Dai J - Search Results

1

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.

Dai J, Liu X, Li J, Qu T, Cui Y, Jin S, Zhang E, Guo R. Dai J, et al. Thorac Cancer. 2023 Feb;14(6):535-543. doi: 10.1111/1759-7714.14783. Epub 2023 Jan 2. Thorac Cancer. 2023. PMID: 36594109 Free PMC article. Review.

2

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Cui Y, Liu X, Wu Y, Liang X, Dai J, Zhang Z, Guo R. Cui Y, et al. Among authors: dai j. Front Oncol. 2022 Mar 10;12:798401. doi: 10.3389/fonc.2022.798401. eCollection 2022. Front Oncol. 2022. PMID: 35359393 Free PMC article.

3

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.

Liang X, Zhang W, Li J, Zhu J, Shao J, Wang J, Wu H, Dai J, Li J, Xu J, Wang W, Guo R. Liang X, et al. Among authors: dai j. J Cancer Res Clin Oncol. 2023 Mar;149(3):1211-1220. doi: 10.1007/s00432-022-03952-z. Epub 2022 Apr 5. J Cancer Res Clin Oncol. 2023. PMID: 35380256

4

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.

Dai J, Cui Y, Liang X, Xu J, Li J, Chen Y, Zhang E, Guo R. Dai J, et al. Front Genet. 2023 Jan 9;13:1066347. doi: 10.3389/fgene.2022.1066347. eCollection 2022. Front Genet. 2023. PMID: 36699446 Free PMC article.

5

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.

Dai J, Qu T, Yin D, Cui Y, Zhang C, Zhang E, Guo R. Dai J, et al. Cell Death Dis. 2023 May 8;14(5):312. doi: 10.1038/s41419-023-05840-x. Cell Death Dis. 2023. PMID: 37156816 Free PMC article.

6

Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.

Chen Y, Zhang C, Jin S, Li J, Dai J, Zhang Z, Guo R. Chen Y, et al. Among authors: dai j. J Cell Mol Med. 2023 Jul;27(14):2032-2044. doi: 10.1111/jcmm.17799. Epub 2023 Jun 6. J Cell Mol Med. 2023. PMID: 37278440 Free PMC article.

7

B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.

Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, Wang W, Zhang E, Guo R. Cui Y, et al. Among authors: dai j. J Exp Clin Cancer Res. 2023 Jun 12;42(1):146. doi: 10.1186/s13046-023-02711-3. J Exp Clin Cancer Res. 2023. PMID: 37303063 Free PMC article.

8

A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network.

Liang X, Guan R, Zhu J, Meng Y, Zhu J, Yang Y, Cui Y, Dai J, Mao W, Lv L, Shen D, Guo R. Liang X, et al. Among authors: dai j. J Cancer Res Clin Oncol. 2023 Oct;149(13):12265-12274. doi: 10.1007/s00432-023-05104-3. Epub 2023 Jul 11. J Cancer Res Clin Oncol. 2023. PMID: 37434091

9

Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.

Liang X, Xu J, Jiang Y, Yan Y, Wu H, Dai J, Cui Y, Zhang C, Chen W, Zhang Z, Guo R. Liang X, et al. Among authors: dai j. Mol Carcinog. 2024 Sep;63(9):1643-1653. doi: 10.1002/mc.23750. Epub 2024 Jun 11. Mol Carcinog. 2024. PMID: 38860603

10

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis.

Dai J, Chen Y, Gong Y, Wei J, Cui X, Yu H, Zhao W, Gu D, Chen J. Dai J, et al. Medicine (Baltimore). 2019 Sep;98(39):e17384. doi: 10.1097/MD.0000000000017384. Medicine (Baltimore). 2019. PMID: 31574891 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,307 results

Search Page

Filters